Jana Kindermans
Overview
Explore the profile of Jana Kindermans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mohaupt P, Kindermans J, Vialaret J, Anderl-Straub S, Werner L, Lehmann S, et al.
Alzheimers Res Ther
. 2024 Dec;
16(1):279.
PMID: 39736793
Introduction: The differentiation between Alzheimer's disease (AD) and behavioral-variant frontotemporal dementia (bvFTD) can be complicated in the initial phase by shared symptoms and pathophysiological traits. Nevertheless, advancements in understanding AD's...
2.
Ultrasensitive and Tracking of C-Labeled PEG-PLA Degradation Products by MALDI-TOF Mass Spectrometry
Khong M, Darcos V, Vialaret J, Ng F, Couture G, Cagnon M, et al.
Biomacromolecules
. 2024 Oct;
25(11):7485-7499.
PMID: 39441127
Copolymers of poly(lactic acid) (PLA) and poly(ethylene glycol) (PEG) are widely used in biomedical applications. As inactive ingredients in formulations, tracking their degradation byproducts stands as a major challenge but...
3.
Giroux P, Vialaret J, Kindermans J, Gabelle A, Bauchet L, Hirtz C, et al.
J Proteome Res
. 2024 Jun;
23(7):2408-2418.
PMID: 38857467
The analysis of protein dynamics or turnover in patients has the potential to reveal altered protein recycling, such as in Alzheimer's disease, and to provide informative data regarding drug efficacy...
4.
Hirtz C, Busto G, Bennys K, Kindermans J, Navucet S, Tiers L, et al.
Alzheimers Res Ther
. 2023 Feb;
15(1):34.
PMID: 36800984
Background: Alzheimer's disease (AD) is a complex neurodegenerative disorder with β-amyloid pathology as a key underlying process. The relevance of cerebrospinal fluid (CSF) and brain imaging biomarkers is validated in...
5.
Thijssen E, Verberk I, Kindermans J, Abramian A, Vanbrabant J, Ball A, et al.
Alzheimers Dement (Amst)
. 2022 May;
14(1):e12285.
PMID: 35603139
Introduction: We explored what combination of blood-based biomarkers (amyloid beta [Aβ], phosphorylated tau [p-tau]181, neurofilament light [NfL], glial fibrillary acidic protein [GFAP]) differentiates Alzheimer's disease (AD) dementia, frontotemporal dementia (FTD),...
6.
Delaby C, Alcolea D, Hirtz C, Vialaret J, Kindermans J, Morichon L, et al.
J Neural Transm (Vienna)
. 2022 Feb;
129(2):231-237.
PMID: 35169889
Introduction: Blood biomarkers represent a major advance for improving the management, diagnosis, and monitoring of Alzheimer's disease (AD). However, their context of use in relation to routine cerebrospinal fluid (CSF)...
7.
Verberk I, Misdorp E, Koelewijn J, Ball A, Blennow K, Dage J, et al.
Alzheimers Dement
. 2021 Nov;
18(8):1484-1497.
PMID: 34845818
Introduction: Pre-analytical sample handling might affect the results of Alzheimer's disease blood-based biomarkers. We empirically tested variations of common blood collection and handling procedures. Methods: We created sample sets that...